Sultamicillin in the treatment of upper respiratory tract infections

ABSTRACT

Forty nine patients, aged 12 years and above, were included in an open non-comparative trial to evaluate the efficacy and safety of sultamicillin in RTI including acute otitis media, acute tonsillitis, acute sinusitis and acute pharyngitis. Each patient received oral sultamicillin, a beta-lactamase inhibitor antibiotic 375mg twice a day in tablet form for 7-12 days. At the end of the study, 47 [96%] paients were clinically cured or improved with bacteria eradicated in 80% of patients, culture-positive at pre-treatment. Signs and symptoms of infection were rapidly resolved particularly temperature which came to normal in 80% of patients on day 3 of the treatment Side effects seen in four patients were mild and did not warrant discontinuation of treatment. Results indicate that sultamicillin is worth-while addition to existing range of oral antibiotics and has the promise to be considered as the antibiotic of choice in upper respiratory tract infections